alanine has been researched along with Melanoma in 26 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 9.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Eristostatin, an RGD-containing disintegrin isolated from the venom of Eristicophis macmahoni, inhibits lung or liver colonization of melanoma cells in a mouse model." | 7.74 | Inhibition of melanoma cell motility by the snake venom disintegrin eristostatin. ( Funk, SE; Galileo, D; McLane, MA; Paquette-Straub, C; Patel, V; Sage, EH; Tian, J, 2007) |
| "The human melanoma cell line FEM-X was selected in multiple steps with VP-16 (etoposide) and an inhibitor of P-glycoprotein (Campain et al." | 7.69 | A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429. ( Campain, JA; Gottesman, MM; Pastan, I, 1994) |
| "The authors conducted a phase II study of L-alanosine in 39 patients (19 without prior chemotherapy) in advanced malignant melanoma." | 7.67 | Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma. ( Ahmann, DL; Creagan, ET; Green, SJ; Long, HJ, 1984) |
| "All eristostatin-treated cells healed less of the wounded area than control conditions." | 5.33 | Scratching below the surface: wound healing and alanine mutagenesis provide unique insights into interactions between eristostatin, platelets and melanoma cells. ( Hensley, B; McLane, MA; Paquette-Straub, C; Srivastava, A; Tian, J; Zelinskas, C; Zhang, X, 2005) |
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 5.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Eristostatin, an RGD-containing disintegrin isolated from the venom of Eristicophis macmahoni, inhibits lung or liver colonization of melanoma cells in a mouse model." | 3.74 | Inhibition of melanoma cell motility by the snake venom disintegrin eristostatin. ( Funk, SE; Galileo, D; McLane, MA; Paquette-Straub, C; Patel, V; Sage, EH; Tian, J, 2007) |
| "The human melanoma cell line FEM-X was selected in multiple steps with VP-16 (etoposide) and an inhibitor of P-glycoprotein (Campain et al." | 3.69 | A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429. ( Campain, JA; Gottesman, MM; Pastan, I, 1994) |
| "The authors conducted a phase II study of L-alanosine in 39 patients (19 without prior chemotherapy) in advanced malignant melanoma." | 3.67 | Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma. ( Ahmann, DL; Creagan, ET; Green, SJ; Long, HJ, 1984) |
| "Melanoma is a kind of aggressive skin neoplasms with high mortality." | 1.72 | LncRNA MSC-AS1, as an oncogene in melanoma, promotes the proliferation and glutaminolysis by regulating the miR-330-3p/ YAP1 axis. ( Ji, G; Luo, B; Shen, G; Tian, T, 2022) |
| "Obesity is associated with increased incidence and worse prognosis of more than one dozen tumor types; however, the molecular mechanisms for this association remain under debate." | 1.51 | Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation. ( Perry, RJ; Rabin-Court, A; Rodrigues, MR; Zhang, XM, 2019) |
| "All eristostatin-treated cells healed less of the wounded area than control conditions." | 1.33 | Scratching below the surface: wound healing and alanine mutagenesis provide unique insights into interactions between eristostatin, platelets and melanoma cells. ( Hensley, B; McLane, MA; Paquette-Straub, C; Srivastava, A; Tian, J; Zelinskas, C; Zhang, X, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (23.08) | 18.7374 |
| 1990's | 8 (30.77) | 18.2507 |
| 2000's | 6 (23.08) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Tian, T | 1 |
| Luo, B | 1 |
| Shen, G | 1 |
| Ji, G | 1 |
| Naser, FJ | 1 |
| Jackstadt, MM | 1 |
| Fowle-Grider, R | 1 |
| Spalding, JL | 1 |
| Cho, K | 1 |
| Stancliffe, E | 1 |
| Doonan, SR | 1 |
| Kramer, ET | 1 |
| Yao, L | 1 |
| Krasnick, B | 1 |
| Ding, L | 1 |
| Fields, RC | 1 |
| Kaufman, CK | 1 |
| Shriver, LP | 1 |
| Johnson, SL | 1 |
| Patti, GJ | 1 |
| Wasinger, C | 1 |
| Hofer, A | 1 |
| Spadiut, O | 1 |
| Hohenegger, M | 1 |
| Rabin-Court, A | 1 |
| Rodrigues, MR | 1 |
| Zhang, XM | 1 |
| Perry, RJ | 1 |
| Madura, F | 1 |
| Rizkallah, PJ | 1 |
| Miles, KM | 1 |
| Holland, CJ | 1 |
| Bulek, AM | 1 |
| Fuller, A | 1 |
| Schauenburg, AJ | 1 |
| Miles, JJ | 1 |
| Liddy, N | 1 |
| Sami, M | 1 |
| Li, Y | 1 |
| Hossain, M | 1 |
| Baker, BM | 1 |
| Jakobsen, BK | 1 |
| Sewell, AK | 1 |
| Cole, DK | 1 |
| Lutz, NW | 1 |
| Banerjee, P | 1 |
| Wilson, BJ | 1 |
| Ma, J | 1 |
| Cozzone, PJ | 1 |
| Frank, MH | 1 |
| Ebert, LM | 1 |
| Liu, YC | 1 |
| Clements, CS | 1 |
| Robson, NC | 1 |
| Jackson, HM | 1 |
| Markby, JL | 1 |
| Dimopoulos, N | 1 |
| Tan, BS | 1 |
| Luescher, IF | 1 |
| Davis, ID | 1 |
| Rossjohn, J | 1 |
| Cebon, J | 1 |
| Purcell, AW | 1 |
| Chen, W | 1 |
| Ostankovitch, M | 1 |
| Robila, V | 1 |
| Engelhard, VH | 2 |
| McLane, MA | 2 |
| Zhang, X | 1 |
| Tian, J | 2 |
| Zelinskas, C | 1 |
| Srivastava, A | 1 |
| Hensley, B | 1 |
| Paquette-Straub, C | 2 |
| Liu, W | 1 |
| Kelly, JW | 1 |
| Trivett, M | 1 |
| Murray, WK | 1 |
| Dowling, JP | 1 |
| Wolfe, R | 1 |
| Mason, G | 1 |
| Magee, J | 1 |
| Angel, C | 1 |
| Dobrovic, A | 1 |
| McArthur, GA | 1 |
| Sage, EH | 1 |
| Funk, SE | 1 |
| Patel, V | 1 |
| Galileo, D | 1 |
| Lamperska, KM | 1 |
| Przybyła, A | 1 |
| Kycler, W | 1 |
| Mackiewicz, A | 1 |
| Creagan, ET | 2 |
| Long, HJ | 1 |
| Ahmann, DL | 1 |
| Green, SJ | 1 |
| Wick, ST | 1 |
| Dubay, MM | 1 |
| Imanil, I | 1 |
| Brizuela, L | 1 |
| Morioka, N | 1 |
| Kikumoto, Y | 1 |
| Hoon, DS | 1 |
| Morton, DL | 1 |
| Irie, RF | 1 |
| Campain, JA | 1 |
| Gottesman, MM | 1 |
| Pastan, I | 1 |
| Kask, K | 1 |
| Berthold, M | 1 |
| Kahl, U | 1 |
| Nordvall, G | 1 |
| Bartfai, T | 1 |
| van Meijer, M | 1 |
| Roelofs, Y | 1 |
| Neels, J | 1 |
| Horrevoets, AJ | 1 |
| van Zonneveld, AJ | 1 |
| Pannekoek, H | 1 |
| Musk, P | 1 |
| Clark, JM | 1 |
| Thompson, D | 1 |
| Dunn, IS | 1 |
| Christopherson, RI | 1 |
| Szabados, E | 1 |
| Rose, SE | 1 |
| Parsons, PG | 1 |
| Herbst, RA | 1 |
| Gutzmer, R | 1 |
| Matiaske, F | 1 |
| Mommert, S | 1 |
| Kapp, A | 1 |
| Weiss, J | 1 |
| Arden, KC | 1 |
| Cavenee, WK | 1 |
| Kittlesen, DJ | 1 |
| Thompson, LW | 1 |
| Gulden, PH | 1 |
| Skipper, JC | 1 |
| Colella, TA | 1 |
| Shabanowitz, J | 1 |
| Hunt, DF | 1 |
| Slingluff, CL | 1 |
| Shabanowitz, JA | 1 |
| Morton, RF | 1 |
| Cullinan, SA | 1 |
| Mailliard, JA | 1 |
| Ebbert, L | 1 |
| Veeder, MH | 1 |
| Chang, M | 1 |
| Lerman, MI | 1 |
| Benyumovich, MS | 1 |
| Schachtschabel, DO | 1 |
| Leising, H | 1 |
| DeWys, WD | 1 |
| Hall, TC | 1 |
| Schulman, JD | 1 |
| Wrathall, JR | 1 |
| Silagi, S | 1 |
| Doores, L | 1 |
1 trial available for alanine and Melanoma
| Article | Year |
|---|---|
Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cimetidine; Drug Evaluation; | 1987 |
25 other studies available for alanine and Melanoma
| Article | Year |
|---|---|
LncRNA MSC-AS1, as an oncogene in melanoma, promotes the proliferation and glutaminolysis by regulating the miR-330-3p/ YAP1 axis.
Topics: Alanine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cysteine; Gene Expression Regulation, | 2022 |
Isotope tracing in adult zebrafish reveals alanine cycling between melanoma and liver.
Topics: Aging; Alanine; Animals; Animals, Genetically Modified; Cell Tracking; Disease Models, Animal; Gluco | 2021 |
Amino Acid Signature in Human Melanoma Cell Lines from Different Disease Stages.
Topics: Alanine; Amino Acids; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Huma | 2018 |
Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation.
Topics: Alanine; Breast Neoplasms; Cell Line, Tumor; Citrate (si)-Synthase; Colonic Neoplasms; Female; Gene | 2019 |
T-cell receptor specificity maintained by altered thermodynamics.
Topics: Alanine; Biotinylation; Crystallography, X-Ray; Gene Expression Regulation, Neoplastic; Humans; Hydr | 2013 |
Expression of Cell-Surface Marker ABCB5 Causes Characteristic Modifications of Glucose, Amino Acid and Phospholipid Metabolism in the G3361 Melanoma-Initiating Cell Line.
Topics: Alanine; Amino Acids; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporte | 2016 |
A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Antigen Presentation; Antigens, Neoplasm; Can | 2009 |
Regulated folding of tyrosinase in the endoplasmic reticulum demonstrates that misfolded full-length proteins are efficient substrates for class I processing and presentation.
Topics: Alanine; Amino Acid Substitution; Animals; Antigen Presentation; Arginine; Cell Line; Cell Line, Tum | 2005 |
Scratching below the surface: wound healing and alanine mutagenesis provide unique insights into interactions between eristostatin, platelets and melanoma cells.
Topics: Alanine; Animals; Binding Sites; Blood Platelets; Cell Line, Tumor; Disintegrins; Humans; Integrins; | 2005 |
Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Child; Female; Gene Frequency; Glutamic Acid; H | 2007 |
Inhibition of melanoma cell motility by the snake venom disintegrin eristostatin.
Topics: Alanine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chorio | 2007 |
The CDKN2a common variants: 148 Ala/Thr and 500 C/G in 3' UTR, and their association with clinical course of melanoma.
Topics: 3' Untranslated Regions; Adult; Aged; Alanine; Amino Acid Substitution; Cyclin-Dependent Kinase Inhi | 2007 |
Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma.
Topics: Alanine; Antibiotics, Antineoplastic; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; | 1984 |
Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16.
Topics: Alanine; Amino Acid Sequence; Binding, Competitive; Carrier Proteins; Cyclin-Dependent Kinase 4; Cyc | 1995 |
Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence.
Topics: Alanine; Amino Acid Sequence; Base Sequence; Epitopes; HLA Antigens; Humans; Melanoma; Molecular Seq | 1995 |
A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429.
Topics: Alanine; Alleles; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Cell Line; | 1994 |
Delineation of the peptide binding site of the human galanin receptor.
Topics: Alanine; Amino Acid Sequence; Animals; Binding Sites; Cell Membrane; Cloning, Molecular; Conserved S | 1996 |
Selective screening of a large phage display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator.
Topics: Alanine; Amino Acid Sequence; Bacteriophages; Base Sequence; Binding Sites; Databases, Factual; DNA, | 1996 |
Purine deoxynucleoside metabolism in human melanoma cells with a high spontaneous mutation rate.
Topics: Alanine; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Survival; Chromatography, High Pre | 1996 |
Further evidence for ultraviolet light induction of CDKN2 (p16INK4) mutations in sporadic melanoma in vivo.
Topics: Alanine; Alleles; Arginine; Carrier Proteins; Cyclin-Dependent Kinase Inhibitor p16; DNA, Neoplasm; | 1997 |
Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.
Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Cancer Vaccines; Cysteine; Cytotoxicity, Immu | 1998 |
Effect of mitomycin C on protein synthesis in human neoplastic cell lines.
Topics: Alanine; Astrocytoma; Dactinomycin; Humans; In Vitro Techniques; Lysine; Melanoma; Mitomycins; Neopl | 1965 |
Proceedings: Growth pattern, melanin synthesis, production of lactate, pyruvate and alanine by 2 lines of Harding Passey melanoma cells in culture.
Topics: Alanine; Animals; Cell Division; Cell Line; Lactates; Melanins; Melanoma; Mice; Neoplasms, Experimen | 1974 |
Anti-tumor effect of the amino acid minosine.
Topics: Alanine; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Dose-Response Relationship, Drug; Ge | 1973 |
Altered amino acid concentrations accompanying suppression of malignancy of mouse melanoma cells by 5-bromodeoxyuridine.
Topics: Alanine; Amino Acids; Animals; Asparagine; Bromodeoxyuridine; Cells, Cultured; Glutamates; Glutamine | 1974 |